USC Norris Comprehensive Cancer Center | Strategic Alliance Partners

April 20, 2025

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

April 19, 2025

In this episode, experts discuss the landmark SARC 032 study, highlighting the importance of multidisciplinary collaboration.

April 18, 2025

In this episode, experts discuss the impact of neoadjuvant radiation and immunotherapy on surgical planning in patients with soft tissue sarcomas.

April 17, 2025

USC Norris Comprehensive Cancer Center has opened Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging, a radiation oncology center.

April 17, 2025

In this episode, experts shed light on the surgical approach to soft tissue sarcomas.

April 16, 2025

In this episode, experts discuss the potential of radiation therapy to enhance immune response in soft tissue sarcomas.

April 15, 2025

In this episode, experts discuss the rationale behind the combined treatment in the Stand Up to Cancer SARC 032 trial.

April 14, 2025

In this episode, experts discuss the latest advancements in the multimodal treatment of undifferentiated pleomorphic sarcoma of the extremities.

April 08, 2025

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

March 21, 2025

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new genetic therapy to treat glioblastoma.

February 25, 2025

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

February 24, 2025

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

February 06, 2025

Dr Lenz discusses the prevalence of RAS mutations in PDAC, the importance of biomarker testing, and treatment advances for patients with this disease.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.

January 30, 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.